Immunotherapy drug shows promise for tough brain cancers
Disease control
Completed
This phase 2 trial tested the immunotherapy drug nivolumab (Opdivo) in 35 adults with recurrent or progressive IDH mutant gliomas that had been previously treated with alkylating agents. The main goal was to see if the drug could shrink tumors. The study is now complete, and resu…
Phase: PHASE2 • Sponsor: Fabio Iwamoto, MD • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC